ARTICLE | Cover Story
A current affair in MS
December 6, 2012 8:00 AM UTC
A European team has used the diabetes drug glibenclamide to block inflammation-induced neurodegeneration in mice.1 The team plans to test the nonspecific inhibitor of the cationic channel TRPM4 in an investigator-led clinical trial in multiple sclerosis and is looking for pharmas to develop more specific antagonists of the target.
Transient receptor potential cation channel subfamily M member 4 (TRPM4) is a widely expressed Ca2+-activated, voltage-dependent cation channel that depolarizes the plasma membrane by increasing sodium influx...